栓塞防护装置 (EPD) 市场：按产品类型、应用、最终用户、地区划分，2024-2031 年

栓塞防护装置 (EPD) 市场评估，2024-2031

由于多种变数，尤其是心血管疾病 (CVD) 盛行率的上升和微创手术的广泛使用，对栓塞防护装置 (EPD) 的需求不断增加。冠状动脉疾病、中风和周边动脉疾病等心血管疾病是全球发病和死亡的主要原因，2024年销售额将达到5.8648亿美元，预计2031年将达到5.8648亿美元。 。

医疗实践中向微创手术的转变极大地增加了对栓塞防护系统的需求。经导管主动脉瓣置换术(TAVR) 和颈动脉支架置放术等微创手术优于传统的开放性手术，因为具有恢復时间更快、住院时间更短、出现问题的可能性更低等优点，因此越来越受欢迎。

栓塞防护装置 (EPD) 市场定义/概述

栓塞防护装置 (EPD) 是一种在心血管治疗过程中使用的医疗装置，用于捕获和清除可能脱落的碎片和栓塞颗粒，尤其是在动脉内。这些装置通常用于颈动脉支架置放术 (CAS)、经皮冠状动脉介入治疗 (PCI) 和其他血管手术中，这些手术中存在清除斑块、血栓或其他碎片的高风险。

它通常用于心血管治疗，以避免栓塞碎片脱落，从而导致中风和重要动脉阻塞等严重问题。EPD 最重要的用途之一是颈动脉支架置放术 (CAS)，用于治疗颈动脉疾病。颈动脉向大脑供应血液，在支架置入过程中，斑块和其他颗粒可能会脱落并进入血液，可能导致中风等栓塞事件。

随着心血管治疗和医疗技术的进步，未来栓塞防护装置 (EPD) 的使用预计将大幅增加。EPD 通常用于颈动脉支架置放术等血管手术中，以回收和清除介入期间可能脱落的碎片，从而降低栓塞性中风的风险。随着世界人口老化和心血管疾病盛行率的增加，对更安全、更有效的介入技术的需求可能会增加。

老年人口的增加会推动栓塞防护装置（EPD）市场吗？

不断增长的老年人口是栓塞防护设备（EPD）市场的主要推动因素。随着人口老化，人们更容易患各种心血管疾病和疾病，这可能需要使用栓塞防护装置（EPD）进行介入治疗。据世界卫生组织(WHO)称，2015年至2050年间，60岁及以上人口的比例将几乎翻倍，从12%增至22%。这相当于60岁及以上的人口从9亿增加到20亿。光是在美国，人口普查局就预测，到 2030 年，所有婴儿潮世代的年龄都将达到 65 岁或以上，即五分之一的老年人。

这一代际变化将对栓塞防护设备（EPD）市场产生重大影响。根据美国疾病管制与预防中心 (CDC) 的数据，心臟病仍然是 65 岁以上人口死亡的主要原因，占该年龄层死亡人数的 25%。此外，根据美国心臟协会的数据，55 岁以后，中风的发生率每 10 年就会增加一倍。这些统计数据表明，老年族群发生心血管事件的风险较高，经常需要颈动脉支架置放术和经导管主动脉瓣置换术 (TAVR) 等治疗。《Journal of the American College of Cardiology》发表的一项研究发现，在 TAVR 手术中使用栓塞保护装置 (EPD) 可将中风风险降低 57%。

严格的监管架构会阻碍栓塞防护装置（EPD）市场吗？

严格的监管框架可能会严重阻碍栓塞防护装置（EPD）市场的成长。EPD 对于减少心血管手术期间的栓塞事件至关重要，特别是对于接受颈动脉支架置放术或经导管主动脉瓣置换术的患者。然而，医疗器材产业监管严格，製造商必须经过复杂的监管流程，导致新产品上市延迟。美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构制定了严格的要求，以确保这些设备的安全性和有效性。这些法规需要严格的临床试验、详尽的文件记录以及持续的上市后监督，这可能既耗时又昂贵。

法规因地区而异，可能会使商业环境变得复杂。欧盟的医疗器材法规 (MDR) 对临床证据和上市后测试提出了更严格的标准，但 FDA 专注于上市前审批和持续监督，这为国际扩张带来了困难。这种不匹配可能会导致产品发布延迟并增加合规成本，从而限制市场扩张。此外，不断更新以适应不断变化的法规的需要可能会耗尽研发资源，并进一步限制创新。虽然这些严格的标准对于病人安全至关重要，但它们也无意中延迟了新颖且可能挽救生命的栓塞保护技术的可用性，限制了它们的采用，并破坏了整体可能减缓传播的速度。

目录

第1章简介

• 市场定义
• 市场细分
• 调查方法

第 2 章执行摘要

• 主要发现
• 市场概况
• 市集亮点

第3章市场概况

• 市场规模和成长潜力
• 市场趋势
• 市场驱动力
• 市场制约因素
• 市场机会
• 波特五力分析

第 4 章 栓塞防护装置 (EPD) 市场：依产品类型

• 远端过滤装置
• 近端封堵器
• 远端封堵器
• 球囊封堵装置

第5章栓塞防护装置 (EPD) 市场（依应用）

• 心血管疾病
• 神经血管疾病
• 週边血管疾病

第 6 章 栓塞防护装置 (EPD) 市场：依最终使用者分类

• 医院
• 门诊手术中心
• 专科诊所
• 其他

第7章 区域分析

• 北美
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东/非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合酋长国

第8章市场动态

• 市场驱动力
• 市场制约因素
• 市场机会
• COVID-19 的市场影响

第9章 竞争格局

• 大公司
• 市场占有率分析

第10章 公司简介

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic Plc
• Edwards Lifesciences Corporation
• W. L. Gore & Associates（Gore Medical）
• Transverse Medical, Inc.
• Innovative Cardiovascular Solutions, LLC
• Allium Medica
• Cardinal Health
• Contego Medical, LLC
• Keystone Heart
• Metactive Medical

第11章市场前景与机遇

• 新兴技术
• 未来市场趋势
• 投资机会

第12章附录

• 缩写表
• 来源和参考文献

Embolic Protection Device Market Valuation - 2024-2031

The need for embolic protection devices (EPDs) is increasing due to several variables, the most notable of which are the rising prevalence of cardiovascular diseases (CVDs) and the expanding use of minimally invasive surgery. Cardiovascular illnesses such as coronary artery disease, stroke, and peripheral artery disease are major sources of morbidity and mortality globally by enabling the market to surpass a revenue of USD 586.48 Million valued in 2024 and reach a valuation of aroundUSD 1022.85 Million by 2031.

The medical field's shift to minimally invasive procedures has greatly boosted demand for embolic protection systems. Minimally invasive methods such as transcatheter aortic valve replacement (TAVR) and carotid artery stenting are gaining popularity over traditional open surgeries due to their related benefits which include shorter recovery times, shorter hospital stays, and a lower chance of problems by enabling the market to grow at aCAGR of 7.20 % from 2024 to 2031.

Embolic Protection Device Market: Definition/ Overview

Embolic Protection Devices (EPDs) are medical equipment used to catch and remove debris or embolic particles that may become dislodged during cardiovascular treatments, particularly in the arteries. These devices are generally employed in procedures such as carotid artery stenting (CAS), percutaneous coronary interventions (PCI), and other vascular surgeries that have a high risk of dislodging plaque, thrombus, or other debris.

They are generally employed in cardiovascular treatments to avoid the migration of embolic debris which can lead to serious problems such as strokes or blockages in critical arteries. One of the most prominent uses for EPDs is in carotid artery stenting (CAS), a treatment used to treat carotid artery disease. The carotid arteries provide blood to the brain, and during stenting, plaque or other particles can dislodge and travel through the bloodstream, potentially causing an embolic event like a stroke.

The future use of embolic protection devices (EPDs) is expected to grow dramatically as advances in cardiovascular care and medical technology progress. EPDs are generally utilized during vascular procedures such as carotid artery stenting to collect and remove debris that may become dislodged during the intervention lowering the risk of an embolic stroke. As the world population ages and cardiovascular disease prevalence rises, there will be a greater demand for safer and more effective interventional methods.

Will the Growing Geriatric Population Drive the Embolic Protection Device Market?

The expanding geriatric population is a primary driver of the embolic protection device market. As people age, they become increasingly vulnerable to a variety of cardiovascular diseases and ailments that may necessitate interventional procedures involving embolic protection devices. According to the World Health Organization (WHO), the share of the world's population over 60 will nearly double between 2015 and 2050 from 12% to 22%. This equates to an increase of 900 million to 2 billion persons over the age of 60. In the United States alone, the Census Bureau predicts that by 2030, all baby boomers will be above the age of 65 growing the elder population to one in every five individuals.

This generational transition has major consequences for the embolic protection device market. According to the Centers for Disease Control and Prevention (CDC), heart disease continues to be the top cause of death among persons aged 65 and older accounting for 25% of all fatalities in this age range. Furthermore, the American Heart Association reports that the incidence of stroke doubles with each decade of life after the age of 55. These statistics show the senior population's higher risk of cardiovascular events which frequently require treatments such as carotid artery stenting or transcatheter aortic valve replacement (TAVR). Research published in the Journal of the American College of Cardiology discovered that using embolic protection devices during TAVR treatments decreased the risk of stroke by 57%.

Will Stringent Regulatory Framework Hamper the Embolic Protection Device Market?

Stringent regulatory frameworks can significantly impede the growth of the embolic protection device (EPD) market. EPDs are crucial for reducing embolic events during cardiovascular procedures, especially in patients having carotid artery stenting or transcatheter aortic valve replacement. However, due to the highly regulated nature of the medical device industry, manufacturers must navigate complex regulatory processes which can cause new product release delays. Regulatory authorities such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) set stringent requirements to ensure the safety and efficacy of these devices. These restrictions necessitate rigorous clinical trials thorough documentation, and ongoing post-market surveillance which can be time-consuming and expensive.

Regulations vary among regions which can complicate the business situation. While the European Union's Medical Device Regulation (MDR) has imposed stronger standards for clinical evidence and post-market inspection, the FDA's emphasis on pre-market approval and continuing monitoring creates a difficult environment for companies wanting to expand abroad. This mismatch might cause product launch delays and increased compliance costs limiting market expansion. Furthermore, the necessity for continual updates to suit changing rules might tap resources away from R&D restricting innovation even further. While these tight standards are vital for patient safety, they can unintentionally slow down the availability of novel and potentially life-saving embolic protection technologies limiting their adoption and slowing the overall expansion.

Category-Wise Acumens

Will Adoption and Effectiveness in Various Cardiovascular Procedures Drive Growth in the Product Type Segment?

Distal filter devices are currently the most dominant product type due to their broad use and effectiveness in a variety of cardiovascular treatments. Distal filter devices are intended to trap embolic debris downstream from the intervention site preventing it from reaching essential organs such as the brain or heart where it could cause catastrophic problems including strokes or myocardial infarctions. Their appeal arises from their capacity to maintain continuous blood flow while filtering out debris which is especially useful in complicated procedures such as carotid artery stenting. These devices are less invasive and easier to use than other types of EPDs making them popular among interventional cardiologists and vascular surgeons.

Furthermore, the form and functionality of distal filter devices help to explain their supremacy. They are frequently more adaptive and versatile allowing for usage in a variety of anatomical situations and procedural scenarios. This versatility is especially useful in the medical industry where patient diversity and procedural complexity necessitate flexible solutions. These devices are suited for a broader spectrum of patients including those with difficult vascular anatomy due to their ease of use and capacity to maintain perfusion throughout the surgery. Furthermore, the rising global frequency of cardiovascular illnesses has increased the demand for effective embolic protection during interventions and distal filter devices are well positioned to address this demand.

Will High Prevalence of Cardiovascular Conditions Drive the Application Segment?

The cardiovascular diseases segment is the most dominant application field owing to the high frequency of cardiovascular illnesses and the important necessity for embolic protection during interventional treatments. Cardiovascular diseases such as coronary artery disease and heart valve problems are major sources of morbidity and mortality worldwide. As a result, there is a high demand for procedures like angioplasty and stenting which are required to treat these problems. While these operations are lifesaving, there is a risk of embolic events which occur when debris dislodges and causes blockages in other sections of the circulatory system.

Furthermore, developments in interventional cardiology have increased the quantity and complexity of cardiovascular treatments driving up demand for EPDs. To avoid complications, innovations like transcatheter aortic valve replacement (TAVR) and sophisticated coronary operations require highly effective embolic protection. The increased use of these advanced procedures, particularly in elderly populations with significant cardiovascular risk highlights the importance of EPDs in this application area. Furthermore, the cardiovascular market benefits from significant investments in research and development resulting in the ongoing advancement of EPD technology.

Country/Region-wise Acumens

Will Rising Cases of Coronary Heart Disease Drive the Market in the North American Region?

The rising prevalence of coronary heart disease (CHD) in North America is driving the market for embolic protection devices. The United States dominates this market because of its advanced healthcare infrastructure, high healthcare spending, and expanding elderly population.

The increasing prevalence of coronary heart disease is a major driver of the embolic protection device market in North America. According to the Centers for Disease Control and Prevention (CDC), approximately 18.2 million adults aged 20 and up in the United States have CHD, accounting for 6.7% of the adult population.

The American Heart Association says that coronary heart disease is the top cause of mortality in the United States accounting for around 13% of all fatalities in 2019. According to the National Heart, Lung, and Blood Institute, the risk of getting coronary heart disease increases with age, especially beyond the age of 55 for women and 45 for men. With North America's aging population, this risk factor is likely to help drive market expansion. According to the United States Census Bureau, by 2030, all baby boomers will be over the age of 65 bringing the total elder population to 73 million people.

Will Improving Healthcare Infrastructure Drive the Market in the Asia Pacific Region?

The Asia Pacific region is seeing the highest growth in the embolic protection device market owing to significant improvements in healthcare infrastructure and increased investments in medical technology. This trend is especially noticeable in rising markets such as China and India. Governments around the Asia Pacific are dramatically expanding their healthcare budgets to enhance access to high-quality medical treatment. According to the World Health Organization, Chinese healthcare spending increased from 5.03% of GDP in 2010 to 6.57% in 2018. Similarly, India's healthcare spending increased from 3.27% to 3.54% of GDP over the same period.

This increasing funding allows hospitals and clinics to invest in modern medical technologies such as embolic protection devices. The Asia Pacific region is experiencing an increase in cardiovascular disease owing to changing lifestyles and an aging population. According to the World Heart Federation, cardiovascular disease accounts for 35% of all deaths in the Asia-Pacific area. Between 2010 and 2030, the number of persons suffering from cardiovascular disease in China is expected to increase by 50%. This increased disease burden is driving up demand for sophisticated therapeutic options such as embolic protection devices.

Competitive Landscape

The Embolic Protection Device Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the embolic protection device market include:

Boston Scientific Corporation

Edwards Lifesciences Corporation.

Abott.

Medtronic

Cardinal Health

Innovative Cardiovascular Solutions, LLC

Transverse Medical, Inc.

L. Gore & Associates, Inc.

Latest Developments

In September 2022, Boston Scientific Corporation revealed the results of a clinical trial on the PROTECTED TAVR to evaluate the SENTINEL Cerebral Protection System, which is designed to capture and eliminate embolic debris from transcatheter aortic valve replacement before it reaches the brain and potentially causes a stroke. Such advances served to maintain the company's brand image while also expanding its consumer base.

In April 2024, Emboline, Inc. announced the acquisition of SWAT Medical's Intellectual Property Portfolio for embolic protection. This acquisition is expected to broaden Emboline's existing portfolio of platform solutions for lowering the risk of stroke caused by the release of embolic debris into the bloodstream during operations like Transcatheter Aortic Valve Replacement (TAVR).

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Embolic Protection Device Market, By Product Type

• Distal Filter Devices
• Proximal Occlusion Devices
• Distal Occlusion Devices
• Balloon Occlusion Devices

5. Embolic Protection Device Market, By Application

• Cardiovascular Diseases
• Neurovascular Diseases
• Peripheral Vascular Diseases

6. Embolic Protection Device Market, By End-User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic Plc
• Edwards Lifesciences Corporation
• W. L. Gore & Associates (Gore Medical)
• Transverse Medical, Inc.
• Innovative Cardiovascular Solutions, LLC
• Allium Medica
• Cardinal Health
• Contego Medical, LLC
• Keystone Heart
• Metactive Medical

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References